Articles On Optiscan Imaging (ASX:OIL)

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

ASX 200 holds steady around +0.8% since lunch Australian Pacific Coal CEO David Conry has left the company. Abruptly. Bain Capital making all the right noises about bringing Virgin back to the bourse   All up, it’s been a pretty tidy old...

ASX 200 edges higher,  small cap index falls 0.44% 7 out of 11 sectors were in the green with Tech up 1.25% Downbeat RBA Governor speech highlights all the things that could go wrong with the economy   Last night the leads were decent, th...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Highlights The S&P/ASX200 closed on a higher note today (25 October), gaining 0.28% to end at 6,798.60 points. Over the last five days, the index has gained 0.29%, but is down 8.68% for the last year to date. A-REIT was the bigges...

Optiscan Imaging (OIL) enters a binding term sheet with Managing Director Professor Camile Farah to acquire intellectual propertyThe intellectual property comes in the form of clinical and histopathological datasets that consists of 228 pat...

ASX closes out the day lower by about 0.74% Online matchmakers Love Group goes on a bodice-busting 39% jag Woman tries to stop eviction with a swarm of bees. No, really…   Aussie markets are set to meander to a close around 0.74% down for...

Optiscan Imaging (ASX:OIL) has announced the submission to the US FDA of a pre-market notification (510(k)) application for the InVivage device intended for oral tissue imaging.

Small cap index up 1.1%, stronger than benchmark, but both do good, run hard.   Wall Street snaps 3-day losing streak, China could be back in stimmy mode Uranium’s gone insanium   The ASX 200 is up 0.7% and the Emerging Companies (XEC) in...

Optiscan Imaging (OIL) submits a Food and Drug Administration (FDA) Pre-Market Notification (510(k)) application for the InVivage device InVisage is a non-invasive, instantaneous form of oral imaging that targets severe health consequences...

Imaging specialist Clarity opens patient recruitment in Australia and will start Phase 2 trial soon Another imaging specialist Optiscan has made a FDA Pre-Market Notification 510(k) submission  Recce Pharma says dosing of Cohort 7 of its P...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The ASX has trundled along like a happy little camper, up nearly 1.0% SZL sizzled then fizzled as the BNPL sector got all turned around So. Many. Quarterlies. Oh. My. God. #pleasemakeitstop   It’s been a happy, smiley Friday for (nearly)...

Small cap index up 3% ASX 200 is up 1% Wall Street jumps as The Fed asks how high The ASX 200 is up 1% and the Emerging Companies (XEC) index is about 3% higher and the wee buy now pay later’s are the heroes of the dish. But first…   Over...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Optiscan Imaging (OIL) releases further information on its new partnership deal at the request of the ASX The company announced yesterday it has penned a distributor partnership with Sinsi Technology for the ViewnVivo device The company to...

Optiscan Imaging (OIL) joins forces with a strategic distribution partner in China The company penned a new distributor partnership with Sinsi Technology for the ViewnVivo device which allows real-time in vivo imaging of living tissue The...

ASX is set to open sharply higher today after Friday’s big rally on Wall Street US major banks pass Fed’s “stress test” On the agenda this week includes OPEC+’s meeting Wall Street leapt higher on Friday, with banks leading the way as the...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

With Tuesday trade in the casket, the ASX Emerging Companies (XEC) index has closed about 1% lower, while the ASX 200 (XJO) benchmark index is down 0.5%, Everywhere markets fell, but for Paris, which has breathed a rich, garlic-scented merd...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

The ASX Emerging Companies (XEC) index is busting out after a three-session losing streak that felt like ten days. I should know, I spent a week in Canberra one afternoon when I was about 15. Anyway, the index for sensational small caps is...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

Optiscan Imaging’s (OIL) Non-Executive Director will step into the role of Managing Director after Darren Lurie announced his resignation Camile Farah’s appointment comes with a fixed remuneration of $385,000 per annum plus superannuation,...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Optiscan Imaging (OIL) completes the patient recruitment and imaging component of its breast cancer margin assessment trial The trial is to test Optiscan’s technology on 38 patients from Melbourne hospitals The main goal is to assess whet...

The ASX 200 Health Index (XHJ) is down by 2.2% at the time of writing, compared to the broader index which is down by 0.60%. AusCann Group (ASX:AC8) is about to commence an exploratory cannabinoid (CBD) trial in people with spinal cord inju...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

In FY21 the ASX 200 returned over 20 per cent but the 100 best performing ASX stocks all gained over 390 per cent and made an average gain of 821 per cent. Stockhead has compiled a list (see below) of the 100 best performing ASX stocks base...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Summary The ASX 200 closed lower by 19 points or 0.27% at 7142.60. The Australian dollar and bond yields rise after the RBA policy decision. The RBA kept interest rates steady at record lows to support the economic growth. Austral...

The USA is the world’s largest healthcare market and therefore a dream for ASX health stocks to enter. This is no easy feat – needing to obtain the approval from the FDA, a regulator renowned as the world’s most sophisticated – but one that...

The diagnostics imaging industry has come a long way since the days of X-rays and CT scans – two technologies that have been around for decades. Although they have not been replaced entirely, a breed of new ASX small caps have emerged over...

For all the leaps and bounds in medical science, the know-how behind detecting diseases hasn’t changed much in decades – or even centuries. Take X-rays, which are widely used despite the wee problem of irradiating the patients. And that’s b...

Summary Oncology player Telix Pharmaceuticals has commenced Phase 3 clinical trial of its prostate cancer therapy candidate. Polymer implants manufacturer Osteopore Limited has obtained CE certification for a significantly broader rang...

Google April 2021 and the first things you’ll find isn’t ASX winners but questions about COVID-19. Just another month in the pandemic, right? Well, yes and no. On one hand the vaccine race continues across the world – far slower than we’d l...

Summary Growth stocks are associated with generating a high return, although the risk associated with the investment is substantially high. Oneview Healthcare recently launched CXP Cloud Enterprise, the world's first and only cloud-bas...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...